Physician profile
Charles E Cornett
NPI 1508870734
$1,511.35
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $19.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $278.27 | 2019 | |
| Amgen INC. | $168.56 | 2019 | |
| Merck Sharp & Dohme LLC | $160.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $138.87 | 2019 | |
| Lilly USA, LLC | $132.51 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.11 | 2019 | |
| Allergan, INC. | $78.37 | 2019 | |
| Amarin Pharma, INC. | $66.14 | 2019 | |
| Astellas Pharma US INC | $58.28 | 2019-2020 | |
| Pfizer INC. | $53.35 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $43.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.81 | 2019 | |
| Glaxosmithkline, LLC. | $33.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.67 | 2019 | |
| Eisai INC. | $24.33 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $23.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.78 | 2019 | |
| Radius Health, INC. | $16.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cornett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.